Race Oncology: Reports $1.8m in cash outflows

Race Oncology Reports $1.8m in cash outflows

  • Race Oncology (RAC) reports $1.8 million in cash outflows for the quarter, an increase from the $931,000 in outflows recorded in the previous quarter
  • The company spent $890,000 during the period for research and development
  • RAC’s focus is Zantrene, a small molecule anti-cancer drug in which the company announced numerous achievements for over the quarter
  • At the end of the period, the company had $37.1 million in cash and cash equivalents
  • Shares closed 2.81 per cent higher today at $2.93 each
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

NatWest Group Strengthens Free Investment Guidance Programme

New initiative aims to educate more customers on investing. Highlights: NatWest Group expands free investment guidance programme.Initiative targets educating...

Tether Launches New Stablecoin Wallet to Enhance User Experience

This innovative platform aims to improve accessibility for crypto users. Highlights: Tether has introduced a new stablecoin wallet.The wallet...

FCA Strengthens Money Laundering Combat with Synthetic Dataset

New collaboration aims to enhance detection capabilities against financial crime. Highlights: FCA partners with Turing Institute to combat money...

Spektr Strengthens Compliance Efforts with $20M Funding

Fintech startup Spektr secures $20 million for AI-driven compliance solutions. Highlights: Spektr raises $20 million to enhance its AI...